Improving the drug development process by reducing the impact of adverse events: the case of cataracts considered

Drug Discovery Today
Andrew F SmithI Michael Wormstone

Abstract

Cataract was used as a model for the prevalence and economic impact of adverse events during the drug development process. Meta-analysis revealed a reported prevalence of cataract at 12.0% (1.0-43.3%), 3.8% (2.4-12.5%), 1.0% (0.0-8.1%), 1.7% (0.0-34.8%) and 3.8% (2.3-5.7%) of compounds in preclinical, Phase I, II, III and IV clinical trials, respectively. Utilising a human-based in vitro screening assay to predict cataractogenic potential in human could allow better selection of novel compounds at early-stage drug development. This could significantly reduce costs and ultimately increase the probability of a drug obtaining FDA approval for a clinical application.

References

Nov 1, 1996·Drug and Chemical Toxicology·S KarlssonG M Williams
Feb 28, 2003·Journal of Health Economics·Joseph A DiMasiHenry G Grabowski
Nov 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patricia Chévez-BarriosRichard L Hurwitz
Mar 1, 2006·Proceedings of the National Academy of Sciences of the United States of America·Paul A SievingRonald A Bush
Sep 19, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L GoreS G Eckhardt
Dec 19, 2006·BMJ : British Medical Journal·Pablo PerelKhalid S Khan
Jan 27, 2007·BMJ : British Medical Journal·Daniel G Hackam
Jul 3, 2007·International Journal of Radiation Oncology, Biology, Physics·Koichi IsobeUNKNOWN Japan Radiation Oncology Group
Jan 26, 2008·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Junping LiBrenda J Tripathi
Mar 10, 2009·American Journal of Ophthalmology·George A WilliamsUNKNOWN Dexamethasone DDS Phase II Study Group
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kala VisvanathanUNKNOWN American Society of Clinical Oncology
Aug 13, 2009·The New England Journal of Medicine·Matthew R SmithUNKNOWN Denosumab HALT Prostate Cancer Study Group
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Koen De GeestWilliam E Richards
Nov 20, 2009·Neurology·S SallowayUNKNOWN Bapineuzumab 201 Clinical Trial Investigators
Jul 22, 2010·International Journal of Radiation Oncology, Biology, Physics·Sacha RothschildI Frank Ciernik
Feb 1, 2006·Environmental Toxicology and Pharmacology·I Michael WormstoneGeorge Duncan
Sep 13, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Arun RajanGiuseppe Giaccone
Feb 15, 2012·Ophthalmology·Quan Dong NguyenUNKNOWN RISE and RIDE Research Group
May 6, 2015·Experimental Eye Research·Ian Michael Wormstone, Julie Ann Eldred

❮ Previous
Next ❯

Citations

Jan 14, 2017·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Hanruo LiuI Michael Wormstone

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Midwife, Health Visitor & Community Nurse
E J Arnott
The Journal of the Oklahoma State Medical Association
C H HARALSON
Nursing Care
L J Carbary
British Medical Journal
P D Trevor-Roper
L' Infirmière canadienne
A Aish
© 2022 Meta ULC. All rights reserved